Cargando…
COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication
Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders—a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed t...
Autores principales: | Rama, Tiago Azenha, Miranda, Joana, Silva, Diana, Amaral, Luís, Castro, Eunice, Coimbra, Alice, Moreira, André, Plácido, José Luís |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146268/ https://www.ncbi.nlm.nih.gov/pubmed/35632474 http://dx.doi.org/10.3390/vaccines10050718 |
Ejemplares similares
-
mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
por: Rama, Tiago Azenha, et al.
Publicado: (2021) -
Case Report: Mastocytosis: The Long Road to Diagnosis
por: Rama, Tiago Azenha, et al.
Publicado: (2021) -
Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
por: Rama, Tiago Azenha, et al.
Publicado: (2022) -
Adrenaline auto-injector prescription and patients’ administration proficiency
por: Amaral, Luis, et al.
Publicado: (2015) -
Jellyfish ingestion was safe for patients with crustaceans, cephalopods, and fish allergy
por: Amaral, Luís, et al.
Publicado: (2018)